-
Product Insights
Familial Amyloid Neuropathies - Drugs In Development, 2024
Empower your strategies with our Familial Amyloid Neuropathies – Drugs In Development, 2024 report and make more profitable business decisions. Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness,...
-
Product Insights
Lipodystrophy (Lipoatrophy) - Drugs In Development, 2024
Empower your strategies with our Lipodystrophy (Lipoatrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Lipodystrophy syndromes comprise a heterogeneous group of disorders characterized by either generalized or partial lack of adipose tissue depending on the type of lipodystrophy. Lipodystrophy has been classified as congenital or acquired. Lipodystrophy syndromes usually manifest with several metabolic abnormalities associated with severe insulin resistance that include diabetes mellitus, hypertriglyceridemia, and hepatic steatosis, which can progress to steatohepatitis. The Lipodystrophy (Lipoatrophy) drugs...
-
Product Insights
Cushing's Syndrome - Drugs In Development, 2024
Empower your strategies with our Cushing's Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps your body respond to stress. This may be caused by a variety of factors like long-term use of corticosteroid medications, tumors in the pituitary gland or adrenal adenomas. The...
-
Product Insights
Hypercholesterolemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Hypercholesterolemia Clinical Trial Report Overview A total of 2407 hypercholesterolemia clinical trials were conducted as of May 2024. The hypercholesterolemia clinical trial report provides a comprehensive understanding of the hypercholesterolemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · Europe · Asia-Pacific · ...
-
Sector Analysis
Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in Major Markets, Disease Overview and Drug Forecast to 2033
Reasons to buy the ‘GLP-1R Agonists in Type 2 Diabetes and Obesity’ market report: The report provides an overview of GLP-1R agonists, type 2 diabetes, and obesity, including epidemiology, symptoms, diagnosis, and disease management. The report includes annualized GLP-1R agonists therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. The report covers key topics including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the...
-
Sector Analysis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period. GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion) Buy the Full Report to Know More about the GLP-1R Agonists in the...
-
Thematic Analysis
Digital Marketing Trends in Type 2 Diabetes
Digital Marketing Trends in Type 2 Diabetes Report Overview Novo Nordisk’s Ozempic.com achieved the highest total traffic across branded type 2 diabetes (T2D) patient sites in the US, from April 2023 to March 2024. This was followed by Rybelsus.com. Overall, the highest proportion of traffic to top branded patient T2D websites originated from direct sources, followed by organic sources. There were a few branded sites in the five major European markets (5EU: France, Germany, Italy, Spain, UK) and Canada (EUCAN)...
-
Sector Analysis
Hyperinsulinemia (HI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Hyperinsulinemia (HI) Marketed and Pipeline Drugs Report Overview Hyperinsulinemia (HI) is a condition wherein the blood insulin level is higher than the level considered normal in people without diabetes. The pancreas produces insulin that controls blood sugar. Although hyperinsulinemia is not diabetes, the condition is often associated with type 2 diabetes (T2D). Key Mechanisms of Action (Marketed) · Receptor Agonist · Transporter Inhibitor Key Molecule Types (Marketed) · Biologic · Small Molecule Key Routes of Administration (Marketed) · Injection · ...
-
Product Insights
Hypertriglyceridemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hypertriglyceridemia Clinical Trial Report Overview A total of 701 Hypertriglyceridemia clinical trials were conducted as of December 2023. The Hypertriglyceridemia clinical trial report provides a comprehensive understanding of the Hypertriglyceridemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe · North America · ...
-
Sector Analysis
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.